Elite Pharmaceuticals, Inc. Reports Results for Third Quarter of Fiscal Year 2017 Pharmaceutical Investing
TRACON Pharmaceuticals Announces Top-line Results from NCI-Sponsored Phase 2 Trial of TRC105 in Recurrent Glioblastoma Pharmaceutical Investing
Sonoma Pharmaceuticals Reports Financial Results for Fiscal Third Quarter 2017 Pharmaceutical Investing
Diffusion Pharmaceuticals’ TSC Phase 1/2 Glioblastoma Multiforme Clinical Trial Results Published in February 2017 Edition of Journal of Neurosurgery Pharmaceutical Investing
BioRestorative Therapies Receives FDA Clearance to Initiate Phase 2 Clinical Trial for the Treatment of Patients with Degenerative Disc Disease Biotech Investing
BriaCell and BriaPro to Present Preclinical Anti-Cancer Activity and Immunotherapy Findings at SITC 2026
